OrthoPediatrics (NASDAQ:KIDS) Major Shareholder Jennifer Pritzker Sells 18,000 Shares of Stock

OrthoPediatrics Corp. (NASDAQ:KIDS) major shareholder Jennifer Pritzker sold 18,000 shares of the firm’s stock in a transaction dated Wednesday, August 26th. The shares were sold at an average price of $24.28, for a total value of $437,040.00. Following the completion of the sale, the insider owned 6,863,464 shares of the company’s stock, valued at approximately $166,644,905.92. This represents a 0.26% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Large shareholders that own more than 10% of a company’s shares are required to disclose their transactions with the SEC.

OrthoPediatrics Price Performance

Shares of NASDAQ:KIDS opened at $24.03 on Thursday. The firm has a market capitalization of $627.42 million, a price-to-earnings ratio of -14.30 and a beta of 0.98. The stock’s 50 day moving average is $21.23 and its 200-day moving average is $18.58. The company has a quick ratio of 2.17, a current ratio of 4.78 and a debt-to-equity ratio of 0.28. OrthoPediatrics Corp. has a twelve month low of $14.42 and a twelve month high of $26.74.

OrthoPediatrics (NASDAQ:KIDS) last issued its quarterly earnings results on Tuesday, August 4th. The company reported ($0.26) EPS for the quarter, beating analysts’ consensus estimates of ($0.30) by $0.04. The company had revenue of $70.51 million during the quarter, compared to the consensus estimate of $68.21 million. OrthoPediatrics had a negative return on equity of 8.10% and a negative net margin of 15.72%. Sell-side analysts forecast that OrthoPediatrics Corp. will post -1.14 EPS for the current fiscal year.

Key OrthoPediatrics News

Here are the key news stories impacting OrthoPediatrics this week:

• Positive Sentiment: OrthoPediatrics completed the full U.S. commercial launch of its 3P™ Pediatric Plating Platform® Hip System after more than 350 successful implantations during a limited release. The company said the system addresses pediatric hip trauma and deformities, improves fixation and surgical workflow, and is the first of several planned systems in a broader plating portfolio. The launch provides a potential long-term revenue and market-share opportunity, although the company did not provide specific financial guidance. OrthoPediatrics Announces Full Commercial Launch of 3P Pediatric Plating Platform Hip System
• Neutral Sentiment: Reported short interest was listed as zero shares with a zero-day short-interest ratio. However, the filing data also showed an invalid “NaN” change, making the statistic unreliable and providing little usable insight into potential short-selling pressure.
• Negative Sentiment: Director David R. Pelizzon and major shareholder entities associated with Squadron Capital and Jennifer N. Pritzker reported sales totaling 38,300 shares for approximately $943,302 across August 24–26, at prices ranging from $24.28 to $25.75. The transactions reduced the reported position by only about 0.56%, leaving ownership of roughly 6.86 million shares, so the sales appear relatively small compared with the remaining stake. Nevertheless, repeated insider selling can weigh on sentiment, particularly with KIDS trading near its 52-week high. SEC insider transaction filing

Analyst Ratings Changes

Several research firms have recently weighed in on KIDS. BTIG Research lifted their target price on shares of OrthoPediatrics from $24.00 to $29.00 and gave the stock a “buy” rating in a research note on Thursday, August 20th. Needham & Company LLC raised their price target on OrthoPediatrics from $30.00 to $35.00 and gave the stock a “buy” rating in a research report on Wednesday, August 5th. Piper Sandler reissued an “overweight” rating and set a $25.00 price target (up from $22.00) on shares of OrthoPediatrics in a research report on Wednesday, August 5th. Truist Financial set a $22.00 price target on shares of OrthoPediatrics in a report on Wednesday, August 5th. Finally, Weiss Ratings raised shares of OrthoPediatrics from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Wednesday, August 5th. Nine investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $26.44.

Institutional Trading of OrthoPediatrics

Several large investors have recently added to or reduced their stakes in KIDS. Millennium Management LLC lifted its position in shares of OrthoPediatrics by 48.0% in the 4th quarter. Millennium Management LLC now owns 1,396,495 shares of the company’s stock worth $24,802,000 after purchasing an additional 452,840 shares during the period. BlackRock Inc. purchased a new stake in OrthoPediatrics in the second quarter worth $24,347,000. Vanguard Group Inc. raised its holdings in OrthoPediatrics by 1.1% in the third quarter. Vanguard Group Inc. now owns 961,330 shares of the company’s stock worth $17,813,000 after purchasing an additional 10,927 shares in the last quarter. Granahan Investment Management LLC raised its holdings in OrthoPediatrics by 35.1% in the first quarter. Granahan Investment Management LLC now owns 896,741 shares of the company’s stock worth $14,231,000 after purchasing an additional 232,760 shares in the last quarter. Finally, Wasatch Advisors LP lifted its position in OrthoPediatrics by 56.6% during the second quarter. Wasatch Advisors LP now owns 515,677 shares of the company’s stock valued at $9,865,000 after buying an additional 186,357 shares during the period. Institutional investors own 69.05% of the company’s stock.

About OrthoPediatrics

OrthoPediatrics Corp., founded in 2007 and headquartered in Warsaw, Indiana, is a medical device company dedicated exclusively to providing orthopedic solutions for children. The company focuses on developing, manufacturing and marketing a broad portfolio of implants and instruments designed to address a wide range of pediatric conditions, including trauma, deformity correction, spine disorders and sports injuries.

The company’s product lines include locking plates and screws for upper and lower extremity reconstruction, intramedullary nails for femur and tibia stabilization, and specialized systems such as the MAGEC Magnetic Growth Rod for treatment of early-onset scoliosis.